GENA-104A16-MMAF

N/A

Report date: 2025/07/02 11:50:28

Base Information

Drug NameGENA-104A16-MMAF

Drug Alias NameGENA-104A16-MMAF

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAF payload

Mechanisms of ActionAnti-Contactin-4Tubulin polymerisation inhibitors

TargetsContactin-4Tubulin

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGenome & Company

China Registration ClassN/A

Develop Information

Active CompaniesGenome & Company

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A